Vitamin D i nivoi proteina koji vezuju vitamin D kod negativnih i pozitivnih pacijenata na odeljenju intenzivne nege COVID-19: prospektivna multicentrična studija
Sažetak
Background:
Vitamin D binding protein plays a crucial role in regulating vitamin D levels by carrying vitamin D and its metabolites and immunological response by binding to endotoxins and fatty acids. We aimed to compare vitamin D, DBP, and specific inflammatory markers among intensive care unit (ICU) patients with and without the COVID-19 virus.
Methods:
This multicenter study conducted in two training and research hospitals included 37 (13 female) COVID-19-positive and 51 (34 female) COVID-19-negative ICU patients. 25(OH) vitamin D, DBP, c-reactive protein (CRP), procalcitonin (PCT), D-dimer, troponin T (TnT), interleukin 6 (IL-6) and ferritin levels, survival, mortality rates, duration of stay (ICU) were examined.
Results:
We observed higher ferritin and CRP levels, along with lower DBP, TnT and D-dimer levels, in patients with COVID-19. ICU patients with COVID-19 exhibited elevated mortality rates (Odds Ratio: 3.012, 95% Confidence Interval [1.252-7.248], p=0.013). However, there was no statistically significant correlation observed between mortality rates and Vitamin D or DBP levels across the entire ICU patient cohort.
Conclusions:
Vitamin d values were found to be low in all intensive care patients, regardless of their covid 19 status. Contrary to the literature, COVID-19 patients had lower D-dimer and TNT levels than negative controls. However, COVID-19-positive ICU patients have decreased DBP. Further DBP gene polymorphisms studies are needed to explain this situation
Sva prava zadržana (c) 2024 Vesile Örnek Diker, Gülseren Yılmaz, Muhammed Emin Düz, Mürvet Algemi, Mehmet Köseoğlu, Hümeyra Öztürk Emre, OSMAN oğuz
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.